# Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants

> **NCT04564053** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Osteoarthritis
- Knee

## Interventions

- **DRUG:** LNA043
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04564053
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-23
- **Primary completion:** 2020-12-10
- **Final completion:** 2020-12-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564053, "Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04564053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*